Kyverna Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Kyverna Therapeutics Inc
Access all reports
Kyverna Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for autoimmune diseases. The company focuses on chimeric antigen receptor (CAR) T-cell therapies, which are designed to reset the immune system and potentially offer sustained treatment-free remission for patients. Kyverna’s main product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently in clinical trials for various autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, Kyverna is developing KYV-201, an allogeneic CAR T-cell therapy, and exploring treatments for other autoimmune diseases including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
KYTX
Country
🇺🇸 United States